Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

NCT05307874 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: ICT01
DRUG: Proleukin Injectable Product
DRUG: Pembrolizumab injection

Sponsor

ImCheck Therapeutics

Collaborators

[object Object]
[object Object]